IMB-1002

N/A

Report date: 2023/10/23 17:37:47

Base Information

Drug NameIMB-1002

Drug Alias NameIMB-1002

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCytokines modulators

TargetsCytokines

Therapy Area/IndicationsLupus Erythematosus, SystemicColitis, Ulcerative

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesN/A

China Registration ClassN/A

Develop Information

Active CompaniesIMIDomics Inc

Inactive CompaniesN/A

Active IndicationsLupus Erythematosus, SystemicColitis, Ulcerative

Inactive IndicationsN/A

Other Information

ATC CodeN/A